Fluoxetine addition to methadone in addicts: pharmacokinetic aspects.


Autoria(s): Bertschy G.; Eap C.B.; Powell K.; Baumann P.
Data(s)

1996

Resumo

We report nine cases where fluoxetine (FX) (20 mg/day) was added to maintenance treatment with methadone (MTD) (dose range: 30-100 mg) in addicts with affective disorders. MTD plasma levels were measured before and after treatment with FX under steady-state conditions. Among the nine patients, two also received fluvoxamine (FLVX) at different times. Although it is possible that in some patients a moderate FX-MTD interaction occurs, resulting in increased plasma levels of MTD, this interaction is certainly less marked than that between FLVX and MTD and unlikely to have clinical consequences.

Identificador

https://serval.unil.ch/?id=serval:BIB_6D3FB791D7AF

isbn:0163-4356 (Print)

pmid:8885121

isiid:A1996VJ25200008

doi:10.1097/00007691-199610000-00008

Idioma(s)

en

Fonte

Therapeutic Drug Monitoring, vol. 18, no. 5, pp. 570-572

Palavras-Chave #Adult; Analgesics, Opioid/pharmacokinetics; Antidepressive Agents, Second-Generation/pharmacokinetics; Drug Interactions; Female; Fluoxetine/administration & dosage; Fluoxetine/pharmacokinetics; Fluvoxamine/administration & dosage; Fluvoxamine/pharmacokinetics; Humans; Male; Methadone/administration & dosage; Methadone/pharmacokinetics; Mood Disorders/blood; Mood Disorders/drug therapy; Serotonin Uptake Inhibitors/pharmacokinetics; Substance-Related Disorders/blood; Substance-Related Disorders/rehabilitation
Tipo

info:eu-repo/semantics/article

article